Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men with Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers Academic Article uri icon

Overview

MeSH Major

  • Cyclooxygenase Inhibitors
  • Prostate
  • Prostatic Neoplasms
  • Pyrazoles
  • Sulfonamides

abstract

  • Treatment with 4 to 6 weeks of celecoxib had no effect on intermediate biomarkers of prostate carcinogenesis, despite the achievement of measurable tissue levels. We caution against using celecoxib 400 mg twice daily as a preventive agent for prostate cancer in additional studies.

publication date

  • October 20, 2009

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC2799055

Digital Object Identifier (DOI)

  • 10.1200/JCO.2009.21.9410

PubMed ID

  • 19720908

Additional Document Info

start page

  • 4986

end page

  • 93

volume

  • 27

number

  • 30